Explore the science
Explore inpegsomatropin, clinical evidence,
and the questions shaping research.
Read the five-study network meta-analysis alongside a forthcoming letter questioning trial identification, omitted safety data, and rare-event rankings. Acceptance of the letter is reported by its author.
Read the analysis →
Research watch / September 2026
A 52-week Phase II basket trial in 78 children reports findings across ISS, SGA, and Turner syndrome.
Read the preliminary findings ↗The population PK/PD study explores dose titration and weight bands through simulation.
Explore the modeling paper ↗The pivotal study
The randomized Phase III trial compared weekly Pegpesen with daily somatropin in treatment-naïve children with GHD. The study met its prespecified non-inferiority criterion for growth velocity.
Study design, outcomes & safety ↗Product reference
Inpegsomatropin injection. Explore composition, presentations, local product information, and the delivery system.
View product information
Explore the reference
Go directly to the information you need, with the source material close at hand.
Composition, presentations, approved local use, dosing, and safety information.
Product reference ↗02 / SCIENCEY-shaped PEGylation, clinical pharmacology, and the principles behind weekly exposure.
Molecule & PK/PD ↗03 / DELIVERYTopPen I, injection workflow, and the connected tools used in treatment management.
Injector & digital care ↗Practical reference
Quick access to administration, monitoring, and safety topics. Clinical use should follow the locally approved prescribing information.
